Pyxis Oncology, Inc.
Clinical trials sponsored by Pyxis Oncology, Inc., explained in plain language.
Clinical-stage biotech developing antibody-drug conjugates for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced cancers? early trial of PYX-201 begins Results expected Apr 2027 (estimated) May already have reported ↗
-
New drug duo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…
Phase 1/2 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for advanced cancers? early trial of PYX-201 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…
Phase 1 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC